Supported by

Catalogue of collaboration profiles

back to list

PomBioTech GmbH

Campus Geb. A1-1
ZIP Code

Company Profile:
PomBioTech is an award winning Biotech CRO located in Saarbrücken Germany. We have specialized on the biotechnological large scale production of drug metabolites (cytochom P450 metabolites and glucuronides) using recombinant yeasts of the species Schizosaccharomyces pombe.
Our scientists have succeeded in functionally expressing a range of important human drug metabolizing enzymes e.g. cytochromes P450, UDP-glucuronosyltransferases (UGT) and hydroxysteroid dehydrogenases (HSD). Using these genetically modified fission yeast strains we are able to offer our clients custom production of drug metabolites (cytochrom P450 metabolites and glucuronides) up to technical scale. Moreover, we also offer the generation of custom made fission yeast stains to meet your demands. Our clients from the pharmaceutical industry benefit from our services since they don’t need to perform time consuming chemical synthesis as well as the subsequent purification of the metabolite of interest.

Biotechnological production of drug metabolites

What we offer:
PomBioTech offers the custom production of drug metabolites using a biotechnological approach. This service is of special interest for ADME-Tox and Pharmacokinetics departments of pharmaceutical companies that are engaged in drug development processes. PomBioTech possesses a comprehensive set of different human cytochromes P450, UDP-glucuronosyltransferases (UGT) and hydroxysteroid dehydrogenases (HSD) expressing fission yeast strains to meet the demands of our customers. Using these strains we are able to offer custom production of drug metabolites up to technical scale as well as inhibitor screening systems.
Besides this we offer the generation of custom fission yeast strains.

What are we looking for:
PomBioTech is looking for partners/clients that can profit from our patented technology. Ideal partners are pharmaceutical companies or academic institutions that are focused on the examination of drug metabolites or pharmacokinetics of APIs.
Our goal is to either investigate whether a certain compound of interested can be metabolized to a desired product using our technology or if a protein of interest can be functionally expressed in fission yeast.

Collaboration sought:
  • Research & Development
  • Joint Venture Agreement
  • Commercial Agreement


Andy Zöllner

Head of Business Development
back to list


Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd

© 2010 ConVerve GmbH | all rights reserved